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Background/Aims: Physiological growth hormone (GH) secretion and IGF-I levels are greater in young 30 
compared to older adults. We evaluated IGF-I levels and predictors of IGF-I responses in young adults on 31 
GH replacement. 32 
Design: From KIMS database, 310 young adults (age, 15-26 years) with the severe GH deficiency related 33 
to childhood-onset disease, and commenced on ‘adult GH replacement’ were identified. ‘IGF-I responses’ 34 
were estimated from first-year increments in IGF-I SDS and adjusted for GH dose. Body composition 35 
was assessed by bioimpedance in 143 patients. 36 
Results: IGF-I levels increased markedly from baseline to 1-year of replacement (-3.75±1.94 vs -37 
1.36±1.86 SDS,p<0.0001), but remained low compared to normative data despite dose titration. In 38 
multivariate models, IGF-I responses were positively associated with age (B [SE] SDS/[mg/m
2
]; 0.52 39 
[0.15],p=0.0007) and BMI SDS (1.06[0.25],p<0.0001), and inversely associated with female gender (-40 
4.45[0.79],p<0.0001) and baseline IGF-I SDS (-1.44[0.20],p<0.0001). IGF-I responses were positively 41 
associated with first-year increases in lean body mass (r=0.19,p=0.003) and HbA1c (r=0.15,p=0.031). 42 
Conclusions: Low IGF-I levels in young adults on treatment may reflect suboptimal GH replacement. 43 
Identification of predictors for IGF-I responses could lead to a more appropriate replacement strategy. 44 
Association between IGF-I responses and lean body mass suggests that maintaining age-appropriate IGF-I 45 




Endogenous Growth Hormone (GH) secretion varies considerably with the developmental state [1]. It 48 
peaks in late puberty, decreases rapidly in the first half of the third decade, and gradually declines 49 
thereafter throughout adult life [2,3]. Circulating levels of insulin-like growth factor-I (IGF-I) follows a 50 
similar pattern [4]. The GH output estimated per unit surface area in young adults is as high as in pre-51 
pubertal children, and almost two-fold greater than in middle-aged adults [2,3]. The post-pubertal state 52 
with the relatively high GH secretion and IGF-I levels corresponds to a period of somatic maturation 53 
which lasts until the middle of the third decade [5,6]. Reductions in lean body mass and bone mineral 54 
density (BMD), and increases in fat mass in patients with childhood-onset GH deficiency (GHD) who 55 
discontinued GH replacement, and physiological rates of accretion of lean body mass and bone mass on 56 
replacement support a critical role of GH in the continued physical development after the completion of 57 
linear growth [5-7]. However, the current recommendations for replacement in young adults with severe 58 
GHD at final height are similar to older adults, and include restarting therapy on a low ‘adult dose’ of GH 59 
(0.2-0.5mg) and titrating to achieve IGF-I levels in the upper half of age- and gender-appropriate normal 60 
ranges (0 to +2 standard deviation scores [SDS]) [8]. Yet, the majority of studies on GH replacement in 61 
young adults used considerably larger doses based on body size (10-25 µkg/kg/day), and the effects of the 62 
current strategy for replacement are not known. 63 
 64 
Young women have 1.5 fold greater endogenous GH secretion compared to young men [9], however, the 65 
IGF-I levels are similar [4] and suggest lower IGF-I responses in women. Age, BMI and sex hormone 66 
replacement are linked to IGF-I responses to GH in older adults [10], however, their impact on IGF-I 67 
titrated GH treatment in young adults are not known. Although IGF-I levels are used to guide GH dose 68 
titration in adults, its relationship with clinical outcomes or adverse effects are poor [10]. In contrast, IGF-69 
I levels are a sensitive marker of GHD in young adults compared to older adults [11], but, the relationship 70 
between IGF-I responses and other treatment outcomes in young adults have not been studied. The aim of 71 
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the study was to determine the IGF-I levels on GH replacement, the factors associated with IGF-I 72 
responses to GH, and the relationship between IGF-I responses and changes in body composition or 73 
glucose metabolism in young adults.  74 
Subjects & Methods: 75 
Database 76 
The analyses were performed in the KIMS (Pfizer International Metabolic Database), an international 77 
pharmaco-epidemiological registry established in 1994 for monitoring the long-term clinical and safety 78 
outcomes of GH replacement (Genotropin
®
) in adult patients with GHD, and run until 2013, the details of 79 
which have been described elsewhere [12]. Briefly, the KIMS is based on 14,000 adult GHD patients 80 
from 31 countries and has the data on background characteristics, details of GH therapy, clinical 81 
measurements, quality of life (QoL), adverse events and centrally measured IGF-I levels. The IGF-I 82 
levels and the derived IGF-I SDS values were promptly fed back to the investigators to assist titration of 83 
GH dose. However, the study did not specify or provide any guidance on the treatment, and the starting 84 
dose of GH and the dose increments were decided by the investigators according to the local practice. 85 
Subjects 86 
Young adults aged 15-26 years with childhood-onset disease and evidence of severe GHD on re-87 
evaluation after attainment of final height, and had IGF-I measurements prior to (baseline) and after 1 88 
year of starting adult GH replacement were selected from the KIMS (n=310). GH deficiency was defined 89 
by peak GH levels <5µg/L on a provocation test (n=246), and when the data were not available, by the 90 
presence of ≥2 additional pituitary hormonal deficiencies (n=54) or IGF-I levels ≤-2.0 SDS while off GH 91 
therapy in patients with an organic cause for pituitary dysfunction (n=10) [8,13]. Among patients who 92 
underwent GH provocation tests, a variety of stimuli were used including insulin (58.1% [n=143]), 93 
arginine (15.9% [n=39]), glucagon (8.5% [n=21], GHRH-Arginine (1.6% [n=4]) and others (4.1% 94 
[n=10]) whereas the type of test was not documented in 11.8% [n=29]. The IGF-I levels in patients 95 
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evaluated using the commonly recommended tests for adults [14] (insulin, glucagon or GHRH-Arginine, 96 
[n=168] ) compared with other tests [n=78] were similar (baseline IGF-I SD: -3.84±1.89 vs -3.64±1.50, 97 
p=0.32; IGF-I SDS at 1 year: -1.36±1.93 vs -1.41±1.74, p=0.58). Although we used a higher threshold of 98 
peak GH levels (<5 µg/L) for the diagnosis, only 5.7% (14/246) patients had peak levels in the ≥3 µg/L. 99 
The patients included those who did not receive prior GH replacement (true naïve, n=61) or had previous 100 
GH therapy, but discontinued treatment for >6 months (semi naïve, n=249). The true naïve patients had 101 
childhood-onset pituitary disease (age of onset, 13.0±5.1 years), but GHD was diagnosed (age, 18.0±3.7 102 
years) and GH replacement started (age, 21.0±2.5 years) during adulthood. Appropriate ethics approval 103 
was obtained in each country, the subjects or their parents provided written informed consent and the 104 
study was conducted according to the principles of the Declaration of Helsinki [12]. 105 
 106 
Assessments 107 
The weight, height, and waist and hip circumferences were measured at baseline, and at 1 and 2 years 108 
after GH replacement. The body composition was estimated in a subgroup (n=143) using bioelectrical 109 
impedance analysis (BIA) employing a variety of different instruments in the participating centres. The 110 
QoL was evaluated using QoL-Assessment of GHD in Adults (QoL-AGHDA) questionnaire [14], which 111 
is based on a scale where a lower score represents a higher QoL. Circulating levels of IGF-I, lipids, 112 
fasting glucose and haemoglobin A1c (HbA1c) were also measured at these time points. 113 
Assays 114 
The serum IGF-I and lipids concentrations were measured centrally while blood glucose and HbA1c were 115 
analysed at the participating centres. Serum IGF-I measurements were performed at Kabi Pharmacia, 116 
Stockholm, Sweden during 1994-1997 and at Sahlgrenska University Hospital, Gothenburg, Sweden. 117 
Thereafter. The IGF-I assays used were a radioimmunoassay following acid/ethanol precipitation of IGF 118 
binding proteins (Nichols Institute Diagnostic, San Juan Capistrano, CA, USA) until November 2002 and 119 
a chemiluminescence immunoassay (Nichols advantage system) thereafter as previously reported [4,15]. 120 
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Serum total cholesterol (TC), triglycerides and high-density lipoprotein cholesterol (HDL-C) were 121 
measured as previously described and low-density lipoprotein cholesterol (LDL-C) was calculated by the 122 
Friedewald’s formula [16]. 123 
Calculations 124 
Physiological levels of IGF-I decline markedly from a peak at the end of puberty to the relatively stable 125 
adult levels by the middle of the third decade [4]. As the age of patients at the start of ‘’adult replacement’ 126 
in the study ranged from 15 to 26 years, we used age and gender specific IGF-I SDS estimated using 127 
assay-specific normative data in the calculations [15]. In patients with GHD, an increase in GH dose 128 
results in a linear rise in IGF-I levels [17], however, the dose titration to achieve a target range of IGF-I 129 
levels results in a wide range of GH doses. Therefore, in line with the previous reports [18,19], we 130 
calculated ‘IGF-I response’ as a measure of responsiveness to GH, from the increments in IGF-I SDS 131 
from baseline (when patients were off replacement) to 1 year of replacement, and adjusted for the GH 132 
dose using the formula: IGF-I response = [IGF-I SDS at 1 year - IGF-I SDS at baseline] / [GH dose 133 
(mg/m
2
) at 1 year]. GH doses were adjusted for body surface area estimated using the Mosteller formula. 134 
The BMI SDS was calculated using normative data [20]. 135 
Statistics 136 
Spearman correlation was used to estimate univariate associations and the biserial correlations [21] 137 
between binary and continuous variables. The relationship between oestrogen treatment and IGF-I levels 138 
were adjusted for the number of hormonal deficiencies in a regression model. Prediction models were 139 
developed by multiple linear regression analysis, and a hierarchy of predictive factors was derived by the 140 
all possible regression approach using Mallow’s C(p) criterion for ordering predictive factors as described 141 
by Weisberg [22]. Analyses were performed with SAS software (Statistical Analysis system, version 8.2, 142 
SAS Institute, Cary, NC, USA). Data are expressed as mean±standard deviation (SD) unless otherwise 143 
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specified. The associations between IGF-I responses and changes in body composition and HbA1c were 144 
adjusted for the baseline measurements in regression models. 145 
Results: 146 
Baseline data 147 
The patients were recruited between 1994 and 2011 and the distribution of diagnoses and background 148 
details (n=310, 180 men) are shown in Table 1 & 2. The diagnosis of GHD was made during childhood at 149 
age 13.5±6.4 years, re-evaluated by GH provocation tests at age 20.3±2.6 years and the adult GH 150 
replacement was started (KIMS start) at age 21.2±2.5 years. Isolated GHD was seen in 23.2% (n=72) 151 
patients, whereas 32.2% (n=100) had 1-2 additional hormonal deficiencies and 43.9% (n=138) were 152 
deficient in ≥3 additional pituitary hormones. Deficiencies of TSH, ACTH, LH/FSH and antidiuretic 153 
hormone were seen in 64.5% (n=200), 51.0% (n=158), 62.9% (n=194) and 26.3% (n=81) patients 154 
respectively. Approximately half of the women (n=60, 46.1%) and men (n=82, 45.5%) were on 155 
oestrogens and testosterone treatment respectively. Among the women on oestrogens (n=60), 37 were 156 
treated with hormone replacement therapy (HRT), 21 with combined oral contraceptive pill, and 2 with 157 
oestrogen patches. There were no significant differences between semi naïve and true naïve patients in the 158 
age at start of ‘adult replacement’, GH doses, IGF-I levels at baseline or during treatment (data not 159 
shown). Three patients who were treated for brain tumour had diabetes mellitus. In 33 patients, the IGF-I 160 
levels were estimated by RIA at baseline, but by the chemiluminescence assay at 1 year. However, there 161 
was no significant difference in the IGF-I SDS estimated by the two assays at baseline or at 1 year (data 162 
not shown). 163 
Baseline IGF-I levels 164 
At baseline, the IGF-I levels were very low (-3.75±1.94 SDS) compared to the normative data and were 165 
lower in women compared with men (-4.14±1.86 vs -3.46±1.96 SDS, p=0.0018) (Table 2). The IGF-I 166 
levels were positively associated with peak GH levels on provocation tests (r=0.39, p<0.0001), and were 167 
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lower in patients with deficiencies of ACTH (r=-0.25, p<0.0001), TSH (r=-0.29, p<0.0001), LH/FSH (r=-168 
0.31, p<0.0001) and in those with higher numbers of additional pituitary hormonal deficiencies (r=-0.30, 169 
p<0.0001) (Table 3). The IGF-I levels were positively correlated with lean body mass at baseline, but 170 
were not associated with age, age at diagnosis of GHD, BMI SDS or fat mass. Women on oestrogen 171 
treatment had lower IGF-I levels at baseline compared to other women (-4.74±1.56 SDS vs -3.62±-1.94 172 
SDS, p=0.015). 173 
GH replacement  174 
The GH doses at start were low, however, during the first year of replacement, the doses almost doubled 175 
(at start vs 1-year, 0.26±0.23 vs 0.51±0.28 mg, p<0.0001) (Table 2). The IGF-I levels increased markedly 176 
following GH replacement (baseline vs 1-year, -3.75±1.94 vs -1.36±1.86 SDS, p<0.0001). However, at 1 177 
year of replacement, the levels were considerably lower than the recommended targets (0 to +2SDS) 178 
(Figure-1) and the majority of patients (n=233; 75.2%) had IGF-I SDS <0. Moreover, no further increases 179 
in IGF-I levels were observed at 2-years of replacement (IGF-I SDS: 1-year vs 2-years, -1.36±1.86 vs -180 
1.46±2.03, p-NS). The starting doses of GH were similar in men and women, however, women were on 181 
higher GH doses (0.59±0.34 vs 0.45±0.21 mg, p<0.0001), but had lower IGF-I levels (-1.83±1.81 vs -182 
1.03±1.82 SDS, p=0.0002) compared to men at 1 year. The IGF-I levels were positively associated with 183 
age (r=0.16, p=0.005), waist circumference (r=0.12, p=0.04), waist-hip ratio (r=0.13, p=0.025), and BMI 184 
SDS (r=0.11, p=0.052) (Table 3). In women, oestrogen treatment was not related to IGF-I levels at 1 year 185 
(IGF-I SDS on vs not on oestrogen: -2.02±1.67 vs -1.67±1.92, p=0.56). 186 
 187 
IGF-I responses to GH 188 
The IGF-I responses were lower in women compared with men (p=0.0002), and were inversely related to 189 
baseline IGF-I levels (r=-0.24, p<0.0001) and peak GH levels on provocation tests (r=-0.21, p=0.001) 190 
(Table-3). The responses were positively associated with age (r=0.16, p=0.005), BMI SDS (r=0.12, 191 
p=0.038), waist circumference (r=0.20, p=0.0015) and waist-hip ratio (r=0.15, p=0.019) (Table-3). 192 
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Multivariate regression models were constructed using age, gender, aetiology (idiopathic vs organic 193 
cause), deficiencies of ACTH, LH/FSH, TSH, ADH, number of pituitary hormonal deficiencies, cranial 194 
irradiation, BMI SDS, waist circumference, waist-hip ratio, baseline IGF-I SDS, oestrogen and 195 
testosterone treatment, and duration of treatment. Male gender, older age, greater BMI SDS and lower 196 
IGF-I SDS at baseline independently predicted higher IGF-I responses (R
2
=0.22, p<0.0001) (Table-4). 197 
When the data were analysed separately by gender, significant measures of adiposity in the models were 198 
BMI SDS in men and waist circumference in women (Table-4). In women, oestrogen treatment was not 199 
associated with IGF-I responses. 200 
Changes in body composition and metabolic parameters during GH replacement and the 201 
relationship with IGF-I response 202 
During the first year of GH replacement, waist-hip ratio (p=0.010) and fat mass (p=0.034) decreased 203 
whereas lean body mass (p<0.0001) and BMI SDS (p=0.039) increased (Table-5). Total cholesterol 204 
(p=0.001) and LDL cholesterol (p=0.0003) decreased while HbA1c increased (p=0.001) without 205 
significant changes in fasting blood glucose levels. At 2 years of replacement, the changes in BMI SDS, 206 
lean body mass, total and LDL cholesterol remained significant compared with the baseline whereas 207 
alterations in fat mass were no longer significant. Furthermore, fasting blood glucose levels increased 208 
(p=0.019) and the HbA1c tended to be higher (p=0.08) at 2 years compared to the baseline. The QoL-209 
AGHDA score was lower at 1 and 2 years compared with the baseline (both p<0.0001) suggesting an 210 
improvement in QoL on GH replacement.  211 
 212 
The IGF-I responses were associated with increases in lean body mass (r=0.19, p=0.007) and HbA1c 213 
(r=0.15, p=0.033) during the first year and the first two years of treatment (r=0.28, p=0.003, and r=0.16, 214 
p=0.057 respectively) (Supporting Information, Figure-1). The responses were also positively associated 215 
with increases in BMI SDS during 2 years of replacement (r=0.16, p=0.013). However, IGF-I responses 216 
were not related to changes in fat mass, lipids, fasting blood glucose levels and QoL-AGHDA scores. The 217 
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IGF-I responses were also not associated with changes in body composition or metabolic parameters from 218 
1 to 2 years (data not shown).  219 
Discussion 220 
We explored a large cohort of young adults with GHD and found that IGF-I levels on replacement were 221 
suboptimal. Age, gender, BMI and baseline IGF-I levels predicted IGF-I responses to GH. Furthermore, 222 
IGF-I responses were related to increases in lean body mass and HbA1c during replacement. 223 
 224 
The GH doses at the start of replacement were consistent with the low ‘adult doses’ currently 225 
recommended in young adults[14], but the GH dose titration resulted in a two-fold increase by 1 year. 226 
Despite the availability of IGF-I SDS measurements to the investigators in the KIMS study, the dose 227 
titration was inadequate as the IGF-I levels on replacement were >1SDS below the mean for healthy 228 
individuals during 2 years of treatment. The reasons for insufficient dose titration are not clear in this 229 
study, however, there are several plausible explanations. Lack of robust evidence to define optimal GH 230 
doses in young adults and a low starting dose may hinder titrating to a considerably higher age-231 
appropriate doses compared to older adults. Low IGF-I levels with no patients achieving 50
th
 centile of 232 
normative data in a small prospective study of young adults treated by dose titration (median GH doses 233 
~11µg/kg) [23] and studies using fixed doses showing that the recommended IGF-I levels are achieved 234 
only with doses as high as 25µg/kg suggest that young adults [24,25] require considerably larger doses 235 
than currently used. Treatment concordance was not evaluated in the current study, however satisfactory 236 
IGF-I levels in middle-aged adults from the KIMS (current study vs middle-aged adults, -1.36 SDS vs 237 
+0.8 SDS) on lower GH doses (0.51mg vs 0.43mg) [26] suggest that lower IGF-I responses substantially 238 
contribute to the suboptimal levels on replacement in young adults. Furthermore, a randomised double-239 
blind study reported dose-dependent effects in young adults with the ‘paediatric dose’ (25µg/kg) resulting 240 
in greater effects on fat mass, BMD and IGF-I levels (+1 vs ‘0’ SDS) compared with an ‘adult dose’ 241 
(12.5µg/kg) [24]. Although these findings were not reproduced in an open-label study [25], many studies 242 
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which observed beneficial effects of GH replacement in older adults maintained a mean IGF-I level above 243 
‘0’ SDS [27]. Whereas GHD is associated with adverse cardiovascular and metabolic outcomes [28], low 244 
IGF-I levels in the general population have also been linked to increased risks for type 2 diabetes and 245 
cardiovascular disease [29]. Therefore, suboptimal GH treatment and relative IGF-I deficiency during a 246 
period of somatic development could adversely affect the long-term outcomes. While alternate strategies 247 
using larger starting doses (e.g. continuing the same or half of the dose at final height) [30] and 248 
subsequent down-titration may assist in achieving IGF-I levels within recommended ranges, future 249 
studies should compare the effects of different replacement regimens on body composition, BMD, 250 
cardiovascular health and glucose metabolism.  251 
 252 
Similar to older adults [26], we also observed marked inter-individual differences in GH doses consistent 253 
with variations in IGF-I response in young adults. The findings that IGF-I levels are unrelated to GH 254 
doses is consistent with dose titration according to IGF-I levels as previously reported [26]. Among the 255 
several inter-related factors associated with IGF-I responses to GH, we identified age, gender, BMI SDS 256 
and baseline IGF-ISDS as the independent predictors. Although the prediction model accounted for a 257 
lower proportion of the variance in IGF-I responses compared to similar models for the first-year growth 258 
response in children with idiopathic GHD (22% vs 61%) [22], the patients in our study were 259 
heterogeneous in the underlying diagnoses and possibly the comorbidities. Nevertheless, identification of 260 
the key predictors of IGF-I responses is useful in deciding the starting dose of GH and the incremental 261 
dose changes.  262 
 263 
The findings of increased IGF-I responses with age suggest that physiological age-related declines in GH 264 
secretion are clinically relevant in young adults [2,31] and support a strategy for down-titrating from the  265 
dose at final height. Our cohort was older at the start of adult GH treatment compared to the patients who 266 
undergo the currently recommended seamless childhood-adult transition of GH treatment (20 vs 17 years) 267 
[32]. We speculate that the lower starting dose of GH may have an even greater adverse impact on the 268 
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IGF-I levels in the younger patients. While low IGF-I responses to GH in adolescent girls compared to 269 
boys with GHD have been inferred previously [33,34], our observations suggesting a direct effect of 270 
gender on GH replacement support a gender-appropriate replacement in young adults [18]. Although 271 
gender differences in IGF-I responses are thought to be mediated by oestrogen [35], we did not find an 272 
association with oral oestrogen treatment. Nevertheless, it showed negative associations or trends with 273 
baseline and 1- year IGF-I levels respectively possibly indicating the lack of power of the study or 274 
underreporting of the oral contraceptive use. Observations of increased IGF-I responses linked to 275 
measures of adiposity is particularly relevant to this population with high prevalence of hypothalamic 276 
obesity and are mediated through the effects of hyperinsulinaemia on hepatic IGF-I generation [14]. The 277 
association between lower baseline IGF-I levels and greater IGF-I responses may reflect the severity of 278 
GHD and is supported by a similar relationship with increased growth responses in children [22]. 279 
Although we used clinically relevant parameters, evaluation of other variables related to GH action such 280 
as GH binding protein and insulin levels, and GH receptor gene polymorphisms may provide further 281 
insights [19] into the variations in IGF-I responses to GH.  282 
 283 
Whereas GH doses in the current study are lower than previous studies in young adults (~ 8µg/kg vs 10-284 
25µg/kg), we observed lesser improvements in lean body mass (2.3kg vs 4-5kg) and reductions in fat 285 
mass (0.9kg vs 1.6-5.5kg) [24,36,37], which suggest a dose-dependent effect of GH on body composition. 286 
However, the improvements in lipid profile in the study are similar to other smaller studies [23,24]. Direct 287 
effects of short-term GH therapy on insulin sensitivity may explain our findings of small increases in 288 
HbA1c during replacement [37]. Long-term improvements in the body composition are reported to 289 
reverse the effects on insulin sensitivity, however, these findings are not universal [38,39]. Our findings 290 
of consistent improvements in the QoL-AGHDA scores at 1 and 2 years on replacement extend a previous 291 




The findings that IGF-I responses are related to gains in lean body mass are consistent with the 294 
physiological role of IGF-I in mediating the anabolic actions of GH in skeletal muscles [40]. While GH 295 
signalling in liver influences the IGF-I levels, changes in lipid metabolism represents the direct actions in 296 
adipose tissue, and may explain the lack of associations between IGF-I responses and fat mass or lipid 297 
profile [40]. Although GH actions on glucose metabolism involve both direct and IGF-I mediated 298 
mechanisms, the direct effects on hepatic insulin sensitivity are predominant [41]. We speculate that 299 
common pathways for GH signalling for IGF-I generation and regulation of glucose metabolism in the 300 
liver underlie the association between IGF-I responses and increases in HbA1c [40]. Our findings suggest 301 
that IGF-I responses are a marker of outcomes of GH replacement in young adults, and are consistent 302 
with the high sensitivity of low IGF-I levels in the diagnosis of GHD in young compared to older adults 303 
[8,11].  304 
 305 
This study based on KIMS database has several strengths such as a large cohort of relatively rare, young 306 
adults with GHD [42] which provided sufficient power for multivariate analysis, the data reflecting real-307 
life patient management, and centrally analysed IGF-I levels with the use of appropriate normative data. 308 
However, there are a few limitations mainly related to passively collected data with no reliable measures 309 
of concordance with therapy. The subjects were evaluated by a variety of GH provocation tests, some of 310 
which are not currently recommended in adults, although, their performance in young adults with a 311 
relatively high endogenous GH secretion is not well-defined [14,39,43]. The details the GH assays 312 
performed locally or evaluations for GHD during childhood were also not available. Data on GH 313 
provocation tests were available in only 80% of the patients, and in the remaining cases, we applied well-314 
established criteria for a high likelihood for severe GHD in young adults to increase the study size 315 
[6,8,14]. Despite these drawbacks, the proportion of idiopathic and isolated GHD in our study is similar 316 
to previous studies in young adults [7,24,36]. The different assays for IGF-I used in the study are not 317 
directly comparable, however, we used assay-specific normative data in the analysis. The heterogenicity 318 
in age and diagnoses, and possibly the associated comorbidities in our study population is a potential 319 
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drawback and may reduce the strength of associations we explored, however, they are unlikely to 320 
influence the direction of relationships in this large study. The correlations of individual predictors of 321 
IGF-I responses and the relationship between IGF-I responses and changes in HbA1c were small. 322 
However, our findings are consistent with observations in older adults, reflect plausible biological 323 
mechanisms, and are potentially useful in formulating treatment strategies. Furthermore, when combined, 324 
the effect of the predictors in the prediction model for IGF-I responses explained a clinically significant 325 
proportion of the variance. Although BIA has been validated against DXA [44], the measurements are 326 
limited by the heterogeneous study population and the use of varying instruments [45]. However, our 327 
analysis focussed on the changes in body composition rather than the absolute values.  328 
 329 
In summary, we report novel data on the effects of the current strategy for GH replacement in young 330 
adults with GHD showing suboptimal IGF-I levels on treatment. The associations between the IGF-I 331 
responses to GH and increases in lean body mass suggest that it is a marker for the outcomes of GH 332 
replacement in young adults and that maintaining age appropriate IGF-I levels is important for optimising 333 
the benefits of replacement. The predictors for IGF-I responses that we describe could lead to a more 334 
appropriate GH replacement strategy in young adults.  335 
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Figure legends 473 
 474 
Figure 1: IGF-I levels before and 1 year following GH treatment in females and males. Each dot 475 
represents one patient. Black dots represent the levels prior to replacement and gray dots levels at 1 year 476 
of treatment. The lines represent age and gender-specific normative data of IGF-I levels (-2, -1, 0, +1 and 477 
+2 SDS).   478 
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